Recursion Pharmaceuticals (NASDAQ: RXRX) revenue
Recursion Pharmaceuticals reported revenue of $74.7m for fiscal 2025, 26.9% more than in fiscal 2024 ($58.8m). Since fiscal 2020 its revenue has grown by 1,784.9%, an average growth of 79.9% a year.
Recursion Pharmaceuticals has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $74.7m | +26.9% | −$648.1m | −867.9% |
| 2024 | $58.8m | +32.0% | −$479.0m | −814.1% |
| 2023 | $44.6m | +11.9% | −$350.1m | −785.3% |
| 2022 | $39.8m | +291.5% | −$245.7m | −616.7% |
| 2021 | $10.2m | +156.9% | −$182.8m | −1,795.8% |
| 2020 | $4.0m | — | −$84.6m | −2,135.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Recursion Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Recursion Pharmaceuticals ranks 308th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Recursion Pharmaceuticals, 26.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 306th | CytomX Therapeutics | $76.2m | −44.8% |
| 307th | AbCellera Biologics | $75.1m | 160.6% |
| 308th | Recursion Pharmaceuticals | $74.7m | 26.9% |
| 309th | Electromed | $73.8m | 15.3% |
| 310th | Assembly Biosciences | $72.3m | 153.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Recursion Pharmaceuticals
- How much revenue did Recursion Pharmaceuticals make in fiscal 2025?
- Recursion Pharmaceuticals reported revenue of $74.7m for fiscal 2025, compared with $58.8m in fiscal 2024.
- How much has the revenue of Recursion Pharmaceuticals grown?
- Between fiscal 2020 and fiscal 2025 it went from $4.0m to $74.7m: 1,784.9% more, an average growth of 79.9% a year.
- What was the best year for revenue at Recursion Pharmaceuticals?
- Of its last 6 fiscal years, fiscal 2025, with $74.7m.
- Where does Recursion Pharmaceuticals rank in its sector by revenue?
- It ranks 308th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Recursion Pharmaceuticals come from?
- From the annual report (Form 10-K) that Recursion Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Recursion Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Recursion Pharmaceuticals: the Recursion Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.